Lantern Pharma Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma's publication of Phase 1a data for LP-184 in recurrent glioblastoma establishes a dosing rationale for a planned Phase 1b/2a trial combining LP-184 with spironolactone, a strategy that could improve outcomes for patients with limited treatment options.

Chicago Metrowire Staff
••Healthcare
Lantern Pharma Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, have announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also known as STAR-001, in patients with recurrent glioblastoma (GBM). The study, published in the October 2026 issue of Cancer Research Communications, evaluated 16 patients and found that LP-184 was generally well tolerated, with a recommended expansion dose of 0.39 mg/kg established. Although no objective radiographic responses were observed, one patient remained clinically and radiographically stable for more than 22 months after enrollment, suggesting potential for prolonged disease control in select cases.

The findings also revealed limited drug exposure in brain tumors, which supports further evaluation of LP-184 in combination with spironolactone, an FDA-approved drug that reduced the concentration of LP-184 needed to kill GBM cells by threefold to sixfold in preclinical models. According to the company, these results establish a dosing rationale for a planned Phase 1b/2a trial that will evaluate LP-184 plus spironolactone in patients experiencing their first GBM recurrence. The trial, sponsored by Starlight Therapeutics under an FDA-cleared Investigational New Drug application, will assess safety, pharmacokinetics, and objective response. The combination strategy was developed with support from Lantern’s RADR® AI platform and research collaborators at Johns Hopkins University.

The announcement matters because recurrent glioblastoma remains a devastating disease with few effective treatment options, and the median survival after recurrence is typically less than a year. While the Phase 1a data did not show objective responses, the long-term stability in one patient and the identification of a tolerable dose provide a foundation for the combination approach. The use of spironolactone, a widely available and well-characterized drug, could accelerate clinical development and reduce costs compared with novel agents. Moreover, LP-184 has received FDA Fast Track Designation for GBM and triple-negative breast cancer, along with Orphan Drug Designations for certain central nervous system cancers, underscoring the unmet need and regulatory recognition of the therapy’s potential.

Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184, LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more information on Lantern Pharma, visit Lantern Pharma (NASDAQ: LTRN). The full press release can be viewed at https://ibn.fm/QSF41 and https://ibn.fm/qaLVQ. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.

MissionIR is a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; article and editorial syndication to 5,000+ outlets; enhanced press release enhancement to ensure maximum impact; social media distribution via IBN to millions of social media followers; and a full array of tailored corporate communications solutions. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration